FDA names drugmakers likely blocking access to drug samples

Share this post

(Reuters) – The U.S. Food and Drug Administration on Thursday listed drugmakers, including Celgene Corp, Mylan NV, Gilead Sciences and Novartis AG, who the regulator says are potentially blocking access to samples of their drugs to delay generic competition.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply